The CAV1 Polyclonal Knockout K-562 Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the K-562 chronic myeloid leukemia (CML) blast crisis cell line, in which the CAV1 gene encoding caveolin-1 has been disrupted. This pool of edited cells provides a genetically heterogeneous model for studying loss of caveolin-1 function, avoiding clonal selection biases and reflecting the diversity of knockout events within the population. The product serves as a versatile tool for investigating the roles of caveolin-1 in signal transduction, endocytosis, and oncogenic transformation, particularly in the context of BCR-ABL1-driven leukemia.
The parental K-562 cell line was originally isolated from a 53-year-old female with Philadelphia chromosome-positive CML in blast crisis and represents an immortalized myelogenous leukemia model harboring the BCR-ABL1 fusion oncogene. K-562 cells are extensively used to dissect downstream signaling pathways of BCR-ABL1, evaluate sensitivity to tyrosine kinase inhibitors such as imatinib and dasatinib, and probe mechanisms underlying blast crisis progression. Their lymphoblastoid morphology and rapid proliferation make them a robust host for large-scale functional genomics and drug discovery applications.
Caveolin-1 is a scaffolding protein that forms the principal structural component of caveolae, flask-shaped plasma membrane invaginations critical for cholesterol transport, endocytosis, and compartmentalized signal transduction. CAV1 interacts directly with SRC family kinases, EGFR, integrin beta1, H-RAS, and eNOS, serving as a platform for caveolin-dependent organization of signaling complexes. The upstream regulators of CAV1 include TGF-beta, insulin, TNF-alpha, and cholesterol, while its downstream targets encompass ERK1/2, AKT, STAT3, Rho GTPases, cyclin D1, MYC, and p53. Mechanistically, CAV1 knockout ablates caveolae, disrupting the spatial coordination of growth factor and integrin signaling, thereby attenuating downstream ERK and AKT activation and altering cell-cycle progression and apoptosis.
In K-562 cells, which depend on BCR-ABL1-mediated activation of the Ras-ERK and PI3K-AKT pathways for proliferation and survival, CAV1 knockout provides a powerful system to delineate the contribution of caveolae-dependent signal regulation to leukemogenic signaling. Loss of caveolin-1 may counteract BCR-ABL1-driven transformation by reducing efficient activation of ERK and AKT, impairing cell-cycle progression via MYC and cyclin D1 downregulation, and enhancing apoptotic susceptibility. This model further enables exploration of whether CAV1 modulates receptor tyrosine kinase crosstalk with EGFR or PDGFR and influences sensitivity to tyrosine kinase inhibitors, offering insights into chemoresistance mechanisms.
Typical research applications include leukemia signal transduction studies, chemoresistance profiling, caveolae-dependent endocytosis assays, and functional analysis of CAV1-interacting partners such as EGFR and SRC. The polyclonal knockout population is suited for Western blotting to confirm CAV1 depletion and assess phosphorylation of ERK, AKT, and STAT3; RT-qPCR to quantify MYC and CCND1; immunofluorescence to examine caveolin-1 localization; co-immunoprecipitation to validate CAV1-EGFR complexes; flow cytometry for apoptosis and cell cycle distribution; transwell migration/invasion assays; and drug sensitivity testing with imatinib or dasatinib. For further details, please contact Ascent Research.
